28.5 C
Australia
Tuesday, October 20, 2020

Novartis, US drug regulator agree to malaria drug trial against Covid-19

Must read

Seek for swimmer lacking at Satan’s Pool

Police started a seek for a person reported lacking after he went swimming on the Babinda Boulders, also referred to as the Satan’s...

Commonwealth Financial institution to beef up enterprise banking

Commonwealth Financial institution will beef up the dimensions of its in-branch enterprise workforce and implement same-day approvals throughout all its enterprise lending merchandise...
The Indian Telegraphhttps://theindiantelegraph.com.au/
Established in 2007, The Indian Telegraph is a multi award winning digital media company based in Australia.

Novartis has won the go-ahead from the U.S. Food and Drug Administration to conduct a randomized trial of malaria drug hydroxychloroquine against COVID-19 disease, the Swiss drugmaker said on Monday, to see if it helps patients.

The decades-old generic medicine got FDA emergency use authorization this month for its unapproved use for coronavirus disease, but so far there is no scientific proof it works. There are currently no approved COVID-19 medicines.

Novartis plans to start recruiting 440 patients for its Phase III, or late-stage, trial within weeks at more than a dozen U.S. sites. Results will be reported as soon as possible, the company added.

Use of the drug, also approved to treat lupus and rheumatoid arthritis, has soared after having been promoted by President Donald Trump, with some worried the administration’s advocacy for an unproven medicine for COVID-19 has short-circuited the FDA’s oversight process.

“We recognize the importance of answering the scientific question of whether hydroxychloroquine will be beneficial for patients with COVID-19 disease,” said John Tsai, Novartis’s top drug developer. “We mobilized quickly to address this question in a randomized, double-blind, placebo-controlled study.”

Companies such as Novartis, Roche and Gilead Sciences are testing older medicines developed to treat other diseases, for signs they could be repurposed to tackle the coronavirus epidemic. Gilead just expanded a trial of its Ebola drug remdesivir.

Still, some fear the championing of hydroxychloroquine by Trump and others as a potential “game changer” against COVID-19 has overshadowed dangerous side effects like vision loss and heart problems. Novartis CEO Vas Narasimhan has also said the medicine is one of his biggest hopes against the viral epidemic.

There are several additional studies of hydroxychloroquine underway, including at the University of Washington and University of Minnesota, as well as work by the National Institutes of Health in the United States.

Novartis’s Sandoz generics unit has pledged to donate 130 million doses of the medicine for use. Sanofi has also said it will donate 100 million doses of hydroxychloroquine to 50 countries.

Latest article

Cricket: Take a look at spinner Nathan Lyon rolled his arm over for the primary time this summer time in Adelaide.

Australia’s Take a look at preparation stepped up in regular vogue in Adelaide as Mitchell Starc had a protracted bowl within the nets,...

Paineful wait is lastly over

Eight months since his final rating of substance, and after an extended wait and a whole bunch of throwdowns, Tim Paine has a...

Jacqui Lambie: ex prime staffer sues for unfair dismissal

Senator Jacqui Lambie’s notorious feedback about liking males who're wealthy, silent and have “a bundle between their legs” have been the start line...

Ex-Sydney instructor groomed boys for intercourse, court docket hears

A Sydney highschool instructor allegedly informed a teenage boy he appeared “attractive” and requested if he thought her breasts have been “too large”...

Cricket: Aussie star Alyssa Healy has to get via the WBBL bubble earlier than she will see husband Mitch Starc once more

Alyssa Healy says she is “too scared” to have a look at a summer season schedule which stays in a state of flux...